3 October  2012
Sareum Holdings plc

(“Sareum” or “the Company”)

Final Results

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce its final results for the year ended 30 June 2012.

Operational Highlights

  • Significant progress on its drug research programmes including:

o    nomination of a pre-clinical development candidate from its Chk1 programme

o    positive in vivo results from its TYK2 programme

  • Presentations of research data at high profile international scientific and business conferences

Financial Highlights

  • £252,500 (before expenses) raised through two share placings
  • Cash at bank and in hand of £511,000 (2011: £871,000)
  • Loss on ordinary activities (after taxation) £651,000 (2011: £568,000 loss) in line with expectations and reflecting planned increase in R&D spend
  • Since the year-end, agreement on a £4m SEDA financing facility from Yorkville Associates (announced 10 September 2012)

Tim Mitchell, Chief Executive Officer of the Company, said: “We have made considerable progress during the year in a number of key areas including seeing positive in-vivo results for our TYK2 programme and the nomination of a development candidate for Chk1.

We continue to focus our efforts on commercialising our research programmes to fuel the future growth of the Company and I remain confident that these efforts will result in the conclusion of one such deal this calendar year.

The addition of the £4 million SEDA financing facility gives us considerable flexibility in funding further development work; hence Sareum is well positioned for the next stage in its corporate development.”


Sareum Holdings plc


Tim Mitchell

01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)


Claire Noyce / Deepak Reddy

020 7947 4350

The Communications Portfolio (Media enquiries)


Philip Ranger / Caolan Mahon

020 7536 2028 / 2029



Annual Results 2012 available as PDF document: Annual Results 2012